FDA's OxyContin Ruling May Spur New Battles Over Generics

Law360, New York (April 23, 2013, 2:54 PM EDT) -- Last week's decision by the U.S. Food and Drug Administration to block generic versions of the oft-abused painkiller OxyContin could embolden makers of other top-selling branded drugs to push the agency to grant them what amounts to a major patent extension by citing safety concerns, drug industry experts say.

Last week, the FDA announced that it would not accept any generic applications based on the original version of Purdue Pharma LP's OxyContin, an opioid painkiller, the same day the patent expired. The agency said it found...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.